2月23日 - ** Vanda Pharmaceuticals VNDA.O股价盘前上涨37%至7.91美元
** 周五晚些时候，美国 FDA 批准了 (link) VNDA 用于治疗两种严重精神疾病的药物
** 该药名为 Bysanti，是一种抗精神病药，主要用于治疗精神分裂症和急性双相情感障碍。
** H.C. Wainwright 分析师表示："Bysanti 的市场独占期预计将延长至 2044 年，这为长期创新和患者获益奠定了坚实的基础。"
** H.C. Wainwright 分析师表示："Vanda 极其有限的企业价值并未反映出该公司已获批准的产品组合的商业潜力，更不用说其广泛的产品线了。"
** 2025 年，VNDA 增长了 84.1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.